Dual GIP & GLP-1 receptor agonist

Tirzepatide

10 mg

Solution for injection
For subcutaneous use only

1 vial Tirzepatide 10 mg  +  1 vial BAC water 3 mL

A single molecule that engages both native incretin pathways, supplied with bacteriostatic water for reconstitution and administered under the direction of a licensed healthcare professional.

Verify your product Read product information
DINOVIA Tirzepatide 10 mg vial in front of its carton.
  • GIP & GLP-1Receptor agonist
  • Store 2–8 °CDo not freeze
  • GMP certifiedControlled manufacture
  • SerializedQR authentication

Product information

Composition & presentation

Each carton holds a single-use vial of tirzepatide and a companion vial of bacteriostatic water.

Carton 120 × 80 × 45 mm. National Drug Code and full labeling are provided in the package insert. Identifiers shown are illustrative and are not a lot release record.

Drug product

Active ingredient
Tirzepatide
Strength
10 mg per vial
Dosage form
Solution for injection
Excipients
Quantum satis, 1 vial
Route
Subcutaneous

Companion diluent

Component
Bacteriostatic water (BAC)
Volume
3 mL
Purpose
Reconstitution / dilution
Status
Sterile · not for use alone

Handling & storage

  • Refrigerate at 2–8 °C. Do not freeze.
  • Protect from light; keep in the original carton.
  • For single-patient use only.
  • Keep out of the reach of children.
  • Do not use if the tamper seal is broken.

Mechanism of action

One molecule, two incretin receptors

By binding both the GIP and GLP-1 receptors, tirzepatide acts on the systems that govern glucose-dependent insulin secretion and appetite regulation.

Receptor

GIP

Glucose-dependent insulinotropic polypeptide signaling contributes to insulin secretion in response to nutrient intake and modulates lipid handling.

Combined effect

Metabolic control

Combined agonism is directed at glycemic control and energy balance, as part of a metabolic management plan supervised by a clinician.

Receptor

GLP-1

Glucagon-like peptide-1 signaling enhances glucose-dependent insulin release, moderates glucagon, and influences gastric emptying and satiety.

This summarizes pharmacologic class and is not a statement of efficacy for any individual patient. Refer to the full Prescribing Information for approved indications, clinical data, and limitations of use.

Quality & manufacturing

Made in a GMP-certified facility

Every batch is produced under a pharmaceutical quality system aligned with current Good Manufacturing Practice. Each stage, from raw-material qualification through fill-finish and release testing, is documented and controlled.

  • Primary packagingPremium-grade components engineered to protect the drug product.
  • LabelingHigh-resolution, durable printing with tamper-evident closure.
  • Anti-counterfeit stickerQR code and serial number for verifiable provenance.
  • TraceabilityEach unit can be traced across the supply chain.

Authenticity & traceability

Verify before you administer

Every carton carries a tamper-evident sticker with an MFG date and a unique serial number. Check them against the registry before use.

  1. Find the sticker on the side of the carton.
  2. Enter the MFG and SERIAL numbers exactly as printed.
  3. Read the result: genuine, not verified, or blocked.
DINOVIA Authenticity check

Results come from the DINOVIA authentication registry. Each check is logged; a code checked many times may indicate a copied sticker.

Important safety information

Please read before use

Boxed warning & contraindications

Refer to the full Prescribing Information for any boxed warning, contraindications, and warnings and precautions. Do not use in individuals for whom the product is contraindicated. Tell your healthcare provider about all medical conditions and medications before starting therapy.

Indication

Approved indications, dosing, and limitations of use are defined in the product’s Prescribing Information. This medicine is available by prescription only and must be used under the supervision of a licensed healthcare professional.

Warnings & precautions

Discuss potential risks, including gastrointestinal effects and other class-related considerations, with your healthcare professional. Seek medical attention for signs of a serious reaction. This website does not provide medical advice and is not a substitute for the package insert.

Reporting

To report a suspected adverse reaction or a product quality complaint, contact your healthcare provider and the manufacturer’s pharmacovigilance line. In the United States, adverse events may also be reported to the FDA at 1-800-FDA-1088.

Clinical, safety, and regulatory statements on this page are illustrative placeholders pending medical and regulatory review, and must be replaced with approved, source-verified labeling before publication.